Loading clinical trials...

COMPLETEDNA

Decentering and Relapse/Recurrence in MBCT for Depression in Adults

The Association Between Decentering and Reductions in Relapse/Recurrence in Mindfulness-Based Cognitive Therapy for Depression in Adults: A Randomized Controlled Trial

NCT05111665•University of British Columbia

View on ClinicalTrials.gov

Summary

Objective: "Decentering" is defined as the ability to observe one's thoughts and feelings as temporary, objective events in the mind, and is increasingly regarded as a candidate mechanism in mindfulness-based interventions. The current study sought to examine the role of decentering, and other related variables, in the efficacy of Mindfulness-based cognitive therapy (MBCT) as compared to two active comparison conditions. Method: Formerly depressed individuals (N = 227), randomly assigned to MBCT (n = 74), relaxation group therapy (RGT; n = 77) or treatment-as-usual (TAU; n = 76), completed self-report measures of decentering and symptoms of depression at pre-, mid-, and post-treatment, and relapse was assessed at 3, 6, 9, and 12 months, post-treatment.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•a Diagnostic and Statistical Manual of Mental Disorders (4th ed.; DSM IV-TR; American Psychiatric Association (APA), diagnosis of major depressive disorder (MDD) without psychotic features, in Full Remission;
•three or more prior major depressive episodes;
•age between 18 and 65 years;
•cognitive reactivity (CR) or mood-activated dysfunctional beliefs score greater than or equal to eight (see assessment procedure below);
•a score of less than 10 on the Hamilton Rating Scale for Depression (HRSD);
•minimum of a 10 week period free of psychotropic medication other than stable dosage of antidepressant medication for a minimum of four weeks;
•fluency in English; An increased cognitive reactivity score of eight points or more and,
•ability to give informed consent and complete questionnaires unassisted.

Exclusion Criteria

•a diagnosis of bipolar disorder (past or present), schizophreniform disorders, substance abuse or dependence (current or within the past six months), borderline or antisocial personality disorder, or neurocognitive disorders;
•current psychotherapy or counselling more frequently than twice per month;
•current practice of meditation more than once per week or yoga more than twice per week;
•electroconvulsive therapy within the past six months; or
•self-reported ingestion of alcohol or other psychoactive substances within the past 48 hrs.

Locations (1)

Mark Lau

Vancouver, British Columbia, Canada

Key Dates

Start Date

February 14, 2008

Primary Completion Date

October 31, 2008

Completion Date

October 31, 2008

Last Updated

November 8, 2021

Enrollment

227

ACTUAL participants

Conditions

DepressionDepressive Disorder, MajorDepression in Remission

Interventions

Mindfulness-based Cognitive Therapy (MBCT)

BEHAVIORAL

Relaxation Group Therapy (RGT)

BEHAVIORAL

Treatment as usual (TAU)

BEHAVIORAL

ACT Together: Implementing a Web-Based Program With Brief Coaching for Parents of Children With Disabilities in Pediatric Outpatient Clinics

NCT07360600

ParentsChildren With Disabilities+2 more

View study

RECRUITINGPHASE3

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

NCT06793397

Major Depressive Disorder (MDD)Depression in Adults+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 8, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Decentering and Relapse/Recurrence in MBCT for Depression in Adults

Inclusion Criteria

Exclusion Criteria

ACT Together: Implementing a Web-Based Program With Brief Coaching for Parents of Children With Disabilities in Pediatric Outpatient Clinics

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

Readiness and Progress in Emotion Regulation Therapy

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression

Serotonin-norepinephrine Reuptake Inhibitor in Prophylaxis of Depression Following Fragility Fractures